ArticleJournal of natural products2025
In Silico Design and Analysis of Cyanobacterial Pseudo Natural Products.
Article in Journal of natural products, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Marine cyanobacteria produce natural products (NPs) with potent and selective bioactivity against a broad range of diseases. However, like many NPs, most exhibit poor drug-like physicochemical properties, and the discovery of structurally novel NPs is declining. To address these challenges, we generated an in silico library of 2,415 cyanobacterial pseudo-NPs by tethering cyanobacterial NP fragments with privileged scaffolds from noncyanobacterial NPs via hypothetical amide bond formation. This library was analyzed using computational platforms to assess predicted physicochemical and ADME/Tox properties, lead-likeness penalties, NP-likeness scores, Tanimoto similarity coefficients, and Synthetic Accessibility Scores. Comparisons to public compound libraries showed that most cyanobacterial pseudo-NPs possess favorable drug- and lead-like characteristics; occupy low-density chemical space; and display unique, synthetically accessible scaffolds. Our results suggest that these pseudo-NPs are promising synthetic targets for drug development. Moreover, this platform can be expanded by using artificial intelligence (AI)-based fragment harvesting tools to create larger libraries of NP-inspired compounds. By integrating cyanobacterial fragments with known bioactive motifs, we aim to bridge the gap between natural diversity and drug-like properties, providing a novel and tractable chemical space for drug discovery efforts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.